We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+79.3%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$1.15B
AUM Growth
+$59.8M
Cap. Flow
-$271M
Cap. Flow %
-23.61%
Top 10 Hldgs %
64.68%
Holding
57
New
16
Increased
6
Reduced
11
Closed
20

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$97.9M
2
NXTC icon
NextCure
NXTC
+$47.4M
3
TGTX icon
TG Therapeutics
TGTX
+$41.3M
4
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$32.8M
5
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$28.6M

Top Sells

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$72.3M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$69.8M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$40.9M
4
PEN icon
Penumbra
PEN
+$40.3M
5
NKTR icon
Nektar Therapeutics
NKTR
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 86.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
51
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-300,000
Closed -$23.4M
MRTX
52
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-300,000
Closed -$23.4M
MYOV
53
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-325,000
Closed -$1.69M
TCDA
54
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-586,929
Closed -$18.1M
TPTX
55
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-222,222
Closed -$8.36M
BOLD
56
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-2,485,000
Closed -$69.8M
MDCO
57
CALL
DELISTED
Medicines Co
MDCO
– –
-1,000,000
Closed -$50M
1 2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2019 Portfolio in Review

As of Q4 2019, Great Point Partners held 57 positions worth $1.15B, up 5.5% from $1.09B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Great Point Partners withdrew a net $271M in Q4 2019, closing 20 positions and reducing 11 holdings. Its most notable exit was Audentes Therapeutics, Inc, an estimated $69.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

Against the trend, Great Point Partners opened a new position in Sage Therapeutics worth $57.5M.

  • Great Point Partners's largest Q4 2019 buy was Sage Therapeutics: 796,057 shares worth $57.5M.
  • Great Point Partners added most to Momenta Pharmaceuticals, Inc. in Q4 2019, an estimated $28.6M increase.
  • Great Point Partners's biggest Q4 2019 reduction was Zogenix, Inc., cutting an estimated $72.3M.
  • Great Point Partners fully exited Audentes Therapeutics, Inc in Q4 2019, selling an estimated $69.8M.
  • Great Point Partners's ten largest holdings make up 65% of its $1.15B portfolio in Q4 2019.
  • Great Point Partners opened 16 new positions and closed 20 in Q4 2019.
  • Great Point Partners's portfolio value rose 5.5% quarter-over-quarter to $1.15B.

Based on Great Point Partners's 13F filing for Q4 2019, filed 14 Feb 2020.